XZP-3287
Small molecule
XZP-3287 is one of 40 small molecule programs targeting Metastasis. It is currently in development.
1
Indications
4
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
159 competitors in Metastasis
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Intron a
Merck & Co.Phase 3
PEG-Intron
Merck & Co.Phase 3
Herceptin
OOrganon and Co
Phase 3
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 3
Vascepa
AAmarin Pharma Inc.
Phase 3
Conmana
BBetta Pharmaceuticals Co., Ltd.
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Lenvima
EisaiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics2 trials
Metastasis1 trial
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
Active, not recruiting·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 1/2·NCT04539496·402 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XZP-3287. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]